RHYTHM PHARMACEUTICALS, INC. 8-K

What Happened
Rhythm Pharmaceuticals, Inc. (RYTM) announced in an 8-K filed April 3, 2026 that its Board elected Kimberly J. Popovits as a non‑employee director effective April 1, 2026. Ms. Popovits will serve as a Class II director through the company’s 2028 annual meeting. On the same date, Edward T. Mathers notified the company of his resignation from the Board, effective April 1, 2026; the filing states his resignation was not due to any disagreement with the company on operations, policies or practices. The company said Ms. Popovits will receive compensation under Rhythm’s standard non‑employee director compensation policy and will enter the company’s standard indemnification agreement.

Key Details

• Appointment effective date: April 1, 2026; Ms. Popovits will hold a Class II seat through the 2028 annual meeting.
• Resignation effective date: April 1, 2026; not caused by disagreement with the company.
• Compensation and indemnification: Ms. Popovits to be paid per the company’s previously filed non‑employee director compensation policy (Exhibit 10.6 to Rhythm’s 2025 Form 10‑K) and will sign the standard indemnification agreement (Exhibit 10.1 to the 2025 Form 10‑K).
• The company furnished a press release about these board changes as Exhibit 99.1 to the 8‑K (filed April 3, 2026).

Why It Matters
Board changes are governance events investors watch because they can influence oversight and strategic direction. This 8‑K documents a routine non‑employee director appointment and a resignation that the company says was not due to any dispute, and it confirms the new director will be subject to the firm’s standard pay and indemnification arrangements. No operational, financial, or executive management changes were announced in this filing.